Terazosin And Metabolic Energetics in Parkinson's Disease

This study investigates if Terazosin can improve metabolism in PD.

Not yet recruiting

Trial opening soon.

Key information

Conditions

Parkinson's Disease (PD) Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

50 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Parkinson's disease

Treatment and study plan

Terazosin 5 MG

Drug

This drug increases glycolysis in Parkinson's disease.

Placebo

Drug

Placebo control for Terazosin

Primary outcomes

ATP

Time frame: at 1.5 year

Changes in whole-blood ATP relative to baseline at 6 weeks and 1.5 years

Study contacts

Contact information is provided by the study sponsor or research team.

Nandakumar Narayanan, MD

CONTACT

[email protected]

+1 319 353 5698

Sponsors and collaborators

Lead sponsor

Nandakumar Narayanan

Other

Registry information

Official study title

Assessing Target Engagement for Terazosin in Parkinson's Disease (TZPD2)

Acronym: TAME-PD:

Important dates

Study start: 2026
Primary completion: 2030
Study completion: 2031
First posted: Mar 11, 2026
Registry last updated: Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not yet recruiting